Venture Investment Plummets In 2009 As VCs Retrench
This article was originally published in The Pink Sheet Daily
Last year was the worst on record since 1997 for venture investment. VCs hold out hope, however, as deal volume and committed dollars increased from Q3 to Q4.
You may also be interested in...
The developer of a Phase III constipation drug wants to raise nearly $270 million in the first week of February. Will it hit a financing home run or strike out?
Venture firms suffered fundraising woes last year, and a handful of biopharma funds stopped investing. It could get worse.
Seattle biotech Omeros ended its first day of trading Oct. 8 at $8.73, down 13 percent after initially pricing its shares at $10, the low end of its expected range